Abstracts - PAGE Meeting (Population Approach Group Europe)

← Back to filters

Abstracts (14)

R.E. Port

Estimating Individual Pretreatment Levels Of A Pharmacologic Response Variable

M. Audran(1) , F. Bressolle (2), R. Gareau (3) and R. Gomeni (4)

A Population Pharmacodynamics Model Of Recombinant Human Erythropoietin In Athletes

Janet R. Wade

Presentation Of Population Analyses For Regulatory Submissions

Farkad Ezzet & Jeffrey Eisele

Inter-Occasion Variation In The Bioavailability Of Benflumetol (An Anti Malarial Drug)

P. Girard, L.B. Sheiner

A Population Markov Model For Analyzing Dose History

Pascal Maire, Roger W. Jelliffe, Xavier Barbaut, Nathalie Bleyzac, Bruno Charpiat, Christine Pivot, Eliane Vermeulen, Pierre Ducrozet, Marie-Aude Confesson, Alain Laffont,

Individualized Drug Therapy And Population Modeling

Mats O. Karlsson1, Tarja Naukkarinen1,2 and Hans Lennernds1

A Population PK/PD Model For The Anti-Parkinsonian Triple Therapy: Levodopa (Ld), Dopadecarboxylase (Ddc) Inhibitor And Catechol-O-Methyl Transferase (Comt) Inhibitor

E. Niclas Jonsson and Mats O. Karlsson

XPose – An S-Plus Based Model Building Aid For Population Analysis With Nonmem

France Mentre, Alain Mallet

Optimal Design In Population Pharmacokinetics

Willi Weber, Lutz Harnisch, Christian Rokitta, Jonathan Collins, H.-Juergen Roethig

Leflunomide Populationpharmacokinetics And Its Interaction With Activated Charcoal/Cholestyramine

Stuart Beal, Ph.D.

Simulating PK/PD Trials

Stuart Beal, Ph.D.

A Preview of NONMEM Version V

C.Pobel* - E.Chatelut+ - B.Tranchand x - J.N. Parola* - S.Demare*

Neural Network Prediction Of Dose And PP Parameters Values From A Population Approach Point Of View: Some Examples And Comments

M. Tod and J.M. Rocchisani

Comparison Of ED, EID, API And Bayesian-API Criteria For The Robust Optimisation Of Sampling Times In Pharmacokinetics.